Psychiatrie pro praxi – 1/2020

www.psychiatriepropraxi.cz  / Neurol. praxi 2019; 20(3): 208–213 / PSYCHIATRIE PRO PRAXI e10 PŘEHLEDOVÉ ČLÁNKY Deprese a migréna: co mají společného? domised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for mi- graine prevention. J Neurol Neurosurg Psychiatry 2016; 87(10):1127–1132. 11. Guglielmo R, Martinotti G, Di Giannantonio M, Janiri L. A possible new option for mig- raine management: agomelatine. Clin Neuropharmacol 2013; 36(2): 65–67. 12. Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007; 27(11): 1293–1300. 13. Harnod T, Lin CL, Kao CH. Risk and Predisposing Factors for Suicide Attempts in Pati- ents with Migraine and Status Migrainosus: A Nationwide Population‑Based Study. J Clin Med 2018; 7(9): 269. 14. Harnod T, Lin CL, Kao CH. Survival outcome and mortality rate in patients with migra- ine: a population‑based cohort study. J Headache Pain 2018; 19(1): 57. 15. Chai NC, Peterlin BL, Calhoun AH. Migraine and estrogen. Curr Opin Neurol 2014; 27(3): 315–324. 16. Jackson JL, Cogbill E, Santana‑Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kues- ter J. A Comparative Effectiveness Meta‑Analysis of Drugs for the Prophylaxis of Migraine Headache. PLoS One 2015; 10(7): e0130733. 17. Jackson JL, Mancuso JM, Nickoloff S, Bernstein R, Kay C. Tricyclic and Tetracyclic Antide- pressants for the Prevention of Frequent Episodic or Chronic Tension‑Type Headache in Adults: A Systematic Review and Meta‑Analysis. J Gen Intern Med 2017; 32(12): 1351–1358. 18. Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, Berbano E, O‚Malley PG. Tricyclic antidepressants and headaches: systematic review and meta‑analysis. BMJ. 2010; 341: c5222. doi:10.1136/bmj.c5222 19. Karlı N, Baykan B, Ertaş M, et al. Impact of sex hormonal changes on tension‑type hea- dache and migraine: a cross‑sectional population‑based survey in 2,600 women. J Hea- dache Pain 2012; 13(7): 557–565. 20. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Pu- blic Health 2013; 34:119–138. 21. Kožený J, Höschl C, Tišanská L. Comorbidity of Migraine and Depression – a Meta­ ‑analysis. Cesk Slov Neurol N 2013; 76/109(6): 712–716. 22. Liu F, Ma T, Che X, Wang Q, Yu S. The Efficacy of Venlafaxine, Flunarizine, and Valproic Acid in the Prophylaxis of Vestibular Migraine. Front Neurol 2017; 8: 524. 23. Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: A syste- matic review. Medicine (Baltimore) 2019; 98(3): e14099. 24. Minen MT, Begasse De DhaemO, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, Silber- sweigD. Migraine and its psychiatric comorbidities. J Neurol NeurosurgPsychiatry 2016; 87: 741–749. 25. Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re‑uptake inhibitors (SSRIs) for pre- ventingmigraine and tension‑type headaches. CochraneDatabase Syst Rev. 2005; (3): CD002919. 26. Nović A, Kõlves K, O‚Dwyer S, De Leo D. Migraine and Suicidal Behaviors: A Systematic Literature Review. Clin J Pain 2016; 32(4): 351–364. 27. Orlova Y, Rizzoli P, Loder E. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. JAMA Neurol 2018; 75(5): 566–572. 28. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of ven- lafaxine in the prophylaxis of migraine. Headache 2005; 45(2): 144–152. 29. Peres MFP, Mercante JPP, Tobo PR, Kamei H, Bigal ME. Anxiety and depression symp- toms and migraine: a symptom‑based approach research. J Headache Pain 2017; 18(1): 37. 30. Plasencia‑García BO, Romero‑Guillena SL, Quirós‑López A, Ruiz‑Doblado S. Agomela- tine and migraine management: a successfully treated case series. Ther Adv Psychophar- macol 2015; 5(4): 243–245. 31. Sacco S, Merki‑Feld GS, Ægidius KL, et al. Effect of exogenous estrogens and progesto- gens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Re- productive Health (ESCRH). J Headache Pain 2018; 19(1): 76. 32. Taylor AP, Adelman JU, FreemanMC. Efficacyof duloxetine as amigrainepreventivemedication: possible predictors of response in a retrospective chart review. Headache 2007; 47(8): 1200–1203. 33. Tomkins GE, Jackson JL, O‚Malley PG, Balden E, Santoro JE. Treatment of chronic hea- dache with antidepressants: a meta‑analysis. Am J Med 2001; 111(1): 54–63. 34. Xu XM, Liu Y, Dong MX, Zou DZ, Wei YD. Tricyclic antidepressants for preventing mig- raine in adults. Medicine (Baltimore) 2017; 96(22):e6989. 35. Yang Y, Zhao H, Heath AC, Madden PA, Martin NG, Nyholt Dr. Shared Genetic Factors Underlie Migraine and Depression. Twin Res Hum Genet 2016; 19(4): 341–350. 36. Yang Y, Zhao H, Heath AC, Madden PA, Martin NG, Nyholt Dr. Familial Aggregation of Migraine and Depression: Insights From a Large Australian Twin Sample. Twin Res Hum Genet 2016; 19(4): 312–321. 37. Young WB, Bradley KC, AnjumMW, Gebeline‑Myers C. Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study. Headache 2013; 53(9): 1430–1437.